Christopher D. O’Brien

2.6k total citations · 1 hit paper
45 papers, 1.9k citations indexed

About

Christopher D. O’Brien is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Christopher D. O’Brien has authored 45 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Genetics, 15 papers in Pulmonary and Respiratory Medicine and 14 papers in Epidemiology. Recurrent topics in Christopher D. O’Brien's work include Inflammatory Bowel Disease (18 papers), Microscopic Colitis (13 papers) and Asthma and respiratory diseases (12 papers). Christopher D. O’Brien is often cited by papers focused on Inflammatory Bowel Disease (18 papers), Microscopic Colitis (13 papers) and Asthma and respiratory diseases (12 papers). Christopher D. O’Brien collaborates with scholars based in United States, United Kingdom and Canada. Christopher D. O’Brien's co-authors include Colleen Marano, Bruce E. Sands, William J. Sandborn, Silvio Danese, Jewel Johanns, Philippe Szapary, Hongyan Zhang, María T. Abreu, Omoniyi J. Adedokun and Remo Panaccione and has published in prestigious journals such as New England Journal of Medicine, The Journal of Cell Biology and Blood.

In The Last Decade

Christopher D. O’Brien

43 papers receiving 1.9k citations

Hit Papers

Ustekinumab as Induction and Maintenance Therapy for Ulce... 2019 2026 2021 2023 2019 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
    2019 787 citations Bruce E. Sands, William J. Sandborn et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher D. O’Brien United States 18 883 667 499 364 320 45 1.9k
John J. Zone United States 41 471 0.5× 985 1.5× 505 1.0× 215 0.6× 92 0.3× 128 5.3k
Thomas A. Lane United States 23 181 0.2× 150 0.2× 399 0.8× 187 0.5× 153 0.5× 90 1.9k
Felipe Andrade United States 26 183 0.2× 193 0.3× 1.2k 2.4× 262 0.7× 189 0.6× 56 2.9k
Kyriakos A. Kirou United States 34 251 0.3× 287 0.4× 2.9k 5.8× 180 0.5× 228 0.7× 73 4.3k
Carrie Fidler United Kingdom 28 383 0.4× 120 0.2× 211 0.4× 159 0.4× 333 1.0× 61 2.8k
Jon Mallen‐St. Clair United States 23 109 0.1× 303 0.5× 694 1.4× 271 0.7× 199 0.6× 72 2.1k
João L. Ascensão United States 21 377 0.4× 173 0.3× 282 0.6× 164 0.5× 149 0.5× 65 1.8k
Antonio Palacı́n Spain 26 142 0.2× 186 0.3× 460 0.9× 451 1.2× 74 0.2× 77 2.5k
Satoru Sagae Japan 28 234 0.3× 401 0.6× 145 0.3× 298 0.8× 50 0.2× 75 3.0k
Maryvonne Dueymes France 21 131 0.1× 83 0.1× 592 1.2× 176 0.5× 340 1.1× 60 1.5k

Countries citing papers authored by Christopher D. O’Brien

Since Specialization
Citations

This map shows the geographic impact of Christopher D. O’Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher D. O’Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher D. O’Brien more than expected).

Fields of papers citing papers by Christopher D. O’Brien

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher D. O’Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher D. O’Brien. The network helps show where Christopher D. O’Brien may publish in the future.

Co-authorship network of co-authors of Christopher D. O’Brien

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher D. O’Brien. A scholar is included among the top collaborators of Christopher D. O’Brien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher D. O’Brien. Christopher D. O’Brien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Danese, Silvio, Bruce E. Sands, María T. Abreu, et al.. (2022). Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial. Clinical Gastroenterology and Hepatology. 20(12). 2858–2867.e5. 24 indexed citations
2.
Panaccione, Remo, Silvio Danese, William J. Sandborn, et al.. (2020). Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. Alimentary Pharmacology & Therapeutics. 52(11-12). 1658–1675. 46 indexed citations
3.
Sandborn, William J., Brian G. Feagan, Silvio Danese, et al.. (2020). Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. Inflammatory Bowel Diseases. 27(7). 994–1007. 77 indexed citations
4.
O’Brien, Christopher D.. (2020). Actuarial valuations to monitor defined benefit pension funding. British Actuarial Journal. 25. 1 indexed citations
5.
Sands, Bruce E., William J. Sandborn, Remo Panaccione, et al.. (2020). Tu1885 EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN BIOLOGIC NAÏVE, BIOLOGIC NON-FAILURE, AND BIOLOGIC FAILURE POPULATIONS THROUGH 2 YEARS: UNIFI LONG-TERM EXTENSION. Gastroenterology. 158(6). S–1203. 2 indexed citations
6.
Sands, Bruce E., Remo Panaccione, Laurent Peyrin‐Biroulet, et al.. (2020). Tu1886 DOSE ADJUSTMENT IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS FROM THE UNIFI MAINTENANCE STUDY LONG-TERM EXTENSION. Gastroenterology. 158(6). S–1204. 1 indexed citations
7.
Volger, Sheri, Ilia Tikhonov, Connie B. Lin, et al.. (2020). Sa1827 PREGNANCY OUTCOMES IN WOMEN WITH PSORIASIS, PSORIATIC ARTHRITIS, CROHN'S DISEASE AND ULCERATIVE COLITIS TREATED WITH USTEKINUMAB. Gastroenterology. 158(6). S–442. 4 indexed citations
8.
9.
Brown, Randall W., Christopher D. O’Brien, Ubaldo J. Martin, Tom Uryniak, & Kathy Lampl. (2012). Long-term safety and asthma control measures with a budesonide/formoterol pressurized metered-dose inhaler in African American asthmatic patients: A randomized controlled trial. Journal of Allergy and Clinical Immunology. 130(2). 362–367.e9. 18 indexed citations
10.
Vogelmeier, Claus, et al.. (2012). A Randomised, Placebo-Controlled, Dose-Finding Study Of AZD9668, An Oral Inhibitor of Neutrophil Elastase, in Patients with Chronic Obstructive Pulmonary Disease Treated with Tiotropium. COPD Journal of Chronic Obstructive Pulmonary Disease. 9(2). 111–120. 76 indexed citations
11.
Vogelmeier, Claus, et al.. (2012). A Randomised, Placebo-Controlled, Dose-Finding Study Of AZD9668, An Oral Inhibitor of Neutrophil Elastase, in Patients with Chronic Obstructive Pulmonary Disease Treated with Tiotropium. COPD Journal of Chronic Obstructive Pulmonary Disease. 1930885945–1930885945. 2 indexed citations
12.
Kuna, Piotr, Martin Jenkins, Christopher D. O’Brien, & William A. Fahy. (2011). AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD. Respiratory Medicine. 106(4). 531–539. 70 indexed citations
13.
Zangrilli, James, Lyndon E. Mansfield, Tom Uryniak, & Christopher D. O’Brien. (2011). Efficacy of budesonide/formoterol pressurized metered-dose inhaler versus budesonide pressurized metered-dose inhaler alone in Hispanic adults and adolescents with asthma: a randomized, controlled trial. Annals of Allergy Asthma & Immunology. 107(3). 258–265.e2. 8 indexed citations
14.
Shah, Shailen, William W. Busse, Jennifer McElhattan, Christopher D. O’Brien, & M. Goldman. (2009). Efficacy and Tolerability of Fixed-Dose (FD) and Adjustable-Dose (AD) Budesonide/Formoterol Pressurized Metered-Dose Inhaler (BUD/FM pMDI) and FD Fluticasone Propionate/Salmeterol Dry Powder Inhaler (FP/SAL DPI) Within Racial Groups. Journal of Allergy and Clinical Immunology. 123(2). S80–S80. 4 indexed citations
15.
Corren, Jonathan, Phillip E. Korenblat, Christopher J. Miller, Christopher D. O’Brien, & William S. Mezzanotte. (2007). Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clinical Therapeutics. 29(5). 823–843. 51 indexed citations
16.
Rosenwasser, Lanny J., Michael Noonan, Paul Martín, L. O'Dowd, & Christopher D. O’Brien. (2007). Safety of Budesonide and Formoterol Administered Via One Pressurized Metered-dose Inhaler (Budesonide/Formoterol pMDI) in Patients (≥12 Years) With Moderate to Severe Persistent Asthma. Journal of Allergy and Clinical Immunology. 119(1). S5–S5. 2 indexed citations
17.
Marcus, Philip, et al.. (2005). Intrapatient symptom variability in adults and children with asthma: Results of a survey. Advances in Therapy. 22(5). 488–497. 2 indexed citations
18.
O’Brien, Christopher D., Gaoyuan Cao, Antonis Makrigiannakis, & Horace M. DeLisser. (2004). Role of immunoreceptor tyrosine-based inhibitory motifs of PECAM-1 in PECAM-1-dependent cell migration. American Journal of Physiology-Cell Physiology. 287(4). C1103–C1113. 50 indexed citations
19.
O’Brien, Christopher D., Guangju Ji, Jing Sun, et al.. (2001). PECAM‐1 (CD31) engagement activates a phosphoinositide‐independent, nonspecific cation channel in endothelial cells. The FASEB Journal. 15(7). 1257–1260. 20 indexed citations
20.
Nakada, Marian T., Kunjlata M. Amin, Melpo Christofidou‐Solomidou, et al.. (2000). Antibodies Against the First Ig-Like Domain of Human Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1) That Inhibit PECAM-1-Dependent Homophilic Adhesion Block In Vivo Neutrophil Recruitment. The Journal of Immunology. 164(1). 452–462. 101 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John J. Zone Breakdown of academic impact, for papers by Thomas A. Lane Breakdown of academic impact, for papers by Felipe Andrade Breakdown of academic impact, for papers by Kyriakos A. Kirou Breakdown of academic impact, for papers by Carrie Fidler Breakdown of academic impact, for papers by Jon Mallen‐St. Clair Breakdown of academic impact, for papers by João L. Ascensão Breakdown of academic impact, for papers by Antonio Palacı́n Breakdown of academic impact, for papers by Satoru Sagae Breakdown of academic impact, for papers by Maryvonne Dueymes
Rankless by CCL
2026